Volume 23, Number 11—November 2017
Dispatch
Polyclonal Pulmonary Tuberculosis Infections and Risk for Multidrug Resistance, Lima, Peru
Table 2
Factors associated with clonal and polyclonal Mycobacterium tuberculosis infection among patients with pulmonary TB, Lima, Peru, September 2009–August 2012*
Characteristic | Clonal aOR (95% CI), n = 115 | p value | Polyclonal aOR (95% CI), n = 161 | p value |
---|---|---|---|---|
Age, y | ||||
15–24 | Referent | Referent | ||
25–34 | 1.21 (0.75–1.96) | 0.44 | 1.40 (0.93–2.11) | 0.11 |
35–44 | 1.16 (0.64–2.11) | 0.62 | 1.42 (0.87–2.31) | 0.16 |
>45 |
1.33 (0.79–2.23) |
0.29 |
1.22 (0.77–1.95) |
0.40 |
Male sex |
0.93 (0.63–1.38) |
0.72 |
1.10 (0.78–1.55) |
0.59 |
Previous TB | 0.82 (0.48–1.37) | 0.45 | 1.27 (0.86–1.86) | 0.23 |
Previous INH receipt | 1.51 (0.54–4.27) | 0.44 | 1.84 (0.82–4.15) | 0.14 |
HIV infection | 0.99 (0.35–2.78) | 0.98 | 1.12 (0.50–2.49) | 0.79 |
≥1 chronic disease |
0.90 (0.55–1.46) |
0.66 |
0.97 (0.64–1.46) |
0.88 |
Hospitalized |
1.01 (0.58–1.75) |
0.97 |
0.98 (0.61–1.57) |
0.93 |
Resistance pattern | ||||
Pansensitive | Referent | Referent | ||
INH or RIF resistance | 1.11 (0.58–2.13) | 0.76 | 1.38 (0.81–2.37) | 0.24 |
Multidrug resistance | 1.24 (0.70–2.22) | 0.46 | 1.66 (1.05–2.62) | 0.03 |
Other | 1.34 (0.77–2.33) | 0.31 | 1.97 (1.27–3.06) | 0.002 |
*Results of multivariable regression analysis using classifier of tandem repeats method. aOR, adjusted odds ratio; INH, isoniazid; RIF, rifampin; TB, tuberculosis.
1These authors contributed equally to this article.